# Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?

> **NCT01991366** · — · WITHDRAWN · sponsor: **Medstar Health Research Institute**

## Conditions studied

- ST-elevation Myocardial Infarction
- Acute Myocardial Infarction

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01991366
- **Lead sponsor:** Medstar Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-10
- **Primary completion:** 2014-10
- **Final completion:** 2021-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of funding
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01991366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01991366, "Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01991366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*